Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?

Key Points

• 11.8% drop: Sarepta shares fell 11.8% to about $20.32 on Thursday with ~2.18M shares traded, leaving a market cap near $2.2 billion.
• While management highlighted a Q1 revenue beat and reiterated its 2026 product outlook, the company posted a large EPS miss (‑$3.58 vs. ‑$0.87) and investors are worried about an Elevidys demand slump and regulatory/safety scrutiny driving the sell‑off.
• Analyst sentiment is mixed — some firms remain cautious (Citi reiterates a Sell with a $13 target) even though the consensus rating is a Hold with an average price target around $30.77.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) dropped 11.8% on Thursday . The company traded as low as $20.53 and last traded at $20.3230. Approximately 2,180,485 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 2,871,157 shares. The stock had previously closed at $23.03.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Q1 beat and outlook maintained — Sarepta reported stronger-than-expected Q1 results (EPS and revenue beats) and reiterated its 2026 product revenue outlook, showing better-than-feared financial execution. Sarepta Q1 2026 Results Press Release
• Neutral Sentiment: Earnings details & presentation — The company provided a slide deck and full earnings-call transcript that explain revenue mix, cost actions and pipeline priorities; useful for investors digging into guidance and margin drivers. Q1 Slide Deck
• Neutral Sentiment: Earnings call coverage available — Transcripts and summaries (Seeking Alpha, Moby) provide management commentary on stabilizing the business and pipeline sequencing, which will be important for assessing recovery timelines. Earnings Call Transcript
• Negative Sentiment: Elevidys demand slump and regulatory scrutiny — Multiple reports say Elevidys sales fell sharply and that a regulatory crackdown is weighing on prescriptions and uptake, a key driver of the stock’s sell-off despite the beat. Sarepta Stock Slumps
• Negative Sentiment: Analyst downgrades / safety overhang — Citi reiterated a Sell and $13 target citing safety and regulatory uncertainty; that negative analyst tone is amplifying downside pressure. Citi Sell Rating
• Neutral Sentiment: Mixed analyst views — Some firms (e.g., J.P. Morgan) maintain neutral/hold ratings noting Elevidys strength in some metrics but offset by pipeline and execution risk; this leaves investor positioning varied. J.P. Morgan Hold Reaffirmed

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen raised Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Weiss Ratings raised Sarepta Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a research note on Wednesday, April 22nd. Royal Bank Of Canada increased their price target on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a "sector perform" rating in a research note on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft increased their price target on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a "sell" rating in a research note on Thursday, March 26th. Finally, Loop Capital set a $25.00 price target on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Hold" and a consensus price target of $30.77.

Sarepta Therapeutics Price Performance

The firm has a market capitalization of $2.20 billion, a P/E ratio of -2.46, a price-to-earnings-growth ratio of 0.33 and a beta of 0.26. The firm has a 50 day moving average price of $19.73 and a 200-day moving average price of $20.32. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. Sarepta Therapeutics's revenue for the quarter was down 32.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 earnings per share. On average, analysts expect that Sarepta Therapeutics, Inc. will post 2.89 earnings per share for the current year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of the firm's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares of the company's stock, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Yousif Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company's stock worth $541,000 after buying an additional 481 shares during the period. Arizona State Retirement System raised its holdings in shares of Sarepta Therapeutics by 2.8% in the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company's stock worth $504,000 after buying an additional 717 shares during the period. Sound View Wealth Advisors Group LLC raised its holdings in shares of Sarepta Therapeutics by 6.1% in the third quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company's stock worth $245,000 after buying an additional 728 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock worth $396,000 after buying an additional 744 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Sarepta Therapeutics by 1.8% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company's stock worth $829,000 after buying an additional 758 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.